Search research articles
Contact Us
Filters
Showing results (101-110 of 418) with videos related to
Page
of 42
Sort By:
Cancer Research
|
February 7, 2007
HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest
Wei Jiang, Peter J Mikochik, Jin H Ra, et al.
The Journal of Investigative Dermatology
|
October 23, 2021
Oncogenic KIT Induces Replication Stress and Confers Cell Cycle Checkpoint Vulnerability in Melanoma
Ching-Ni Njauw, Zhenyu Ji, Duc Minh Pham, et al.
Radiographics : a Review Publication of the Radiological Society of North America, Inc
|
November 14, 2017
Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings
Gary X Wang, Vikram Kurra, Justin F Gainor, et al.
Oncotarget
|
April 19, 2014
Pathways and therapeutic targets in melanoma
Emma Shtivelman, Michael Q A Davies, Patrick Hwu, et al.
Pigment Cell & Melanoma Research
|
October 3, 2018
A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF<sup>high</sup> /AXL<sup>low</sup> melanoma
Michael P Smith, Sareena Rana, Jennifer Ferguson, et al.
Cancer Biology & Therapy
|
January 26, 2008
Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma
Keith T Flaherty, Mark A Rosen, Daniel F Heitjan, et al.
Life Science Alliance
|
August 29, 2022
Proteasomal down-regulation of the proapoptotic MST2 pathway contributes to BRAF inhibitor resistance in melanoma
David Romano, Lucía García-Gutiérrez, Nourhan Aboud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 20, 2016
Parallel In Vivo Assessment of Drug Phenotypes at Various Time Points during Systemic BRAF Inhibition Reveals Tumor Adaptation and Altered Treatment Vulnerabilities
Oliver Jonas, Madeleine J Oudin, Tatsiana Kosciuk, et al.
The Journal of Investigative Dermatology
|
March 8, 2008
Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells
Konstantinos G Lasithiotakis, Tobias W Sinnberg, Birgit Schittek, et al.
Journal of the American Academy of Dermatology
|
July 21, 2015
Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: A study of 19 lesions from 10 patients
Mark C Mochel, Marc R Hammond, Dennie T Frederick, et al.
Page
of 42
Search research articles
Search
Showing results (101-110 of 418) with videos related to
Sort By:
Page
of 42
Cancer Research
|
February 7, 2007
HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest
Wei Jiang, Peter J Mikochik, Jin H Ra, et al.
The Journal of Investigative Dermatology
|
October 23, 2021
Oncogenic KIT Induces Replication Stress and Confers Cell Cycle Checkpoint Vulnerability in Melanoma
Ching-Ni Njauw, Zhenyu Ji, Duc Minh Pham, et al.
Radiographics : a Review Publication of the Radiological Society of North America, Inc
|
November 14, 2017
Immune Checkpoint Inhibitor Cancer Therapy: Spectrum of Imaging Findings
Gary X Wang, Vikram Kurra, Justin F Gainor, et al.
Oncotarget
|
April 19, 2014
Pathways and therapeutic targets in melanoma
Emma Shtivelman, Michael Q A Davies, Patrick Hwu, et al.
Pigment Cell & Melanoma Research
|
October 3, 2018
A PAX3/BRN2 rheostat controls the dynamics of BRAF mediated MITF regulation in MITF<sup>high</sup> /AXL<sup>low</sup> melanoma
Michael P Smith, Sareena Rana, Jennifer Ferguson, et al.
Cancer Biology & Therapy
|
January 26, 2008
Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma
Keith T Flaherty, Mark A Rosen, Daniel F Heitjan, et al.
Life Science Alliance
|
August 29, 2022
Proteasomal down-regulation of the proapoptotic MST2 pathway contributes to BRAF inhibitor resistance in melanoma
David Romano, Lucía García-Gutiérrez, Nourhan Aboud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 20, 2016
Parallel In Vivo Assessment of Drug Phenotypes at Various Time Points during Systemic BRAF Inhibition Reveals Tumor Adaptation and Altered Treatment Vulnerabilities
Oliver Jonas, Madeleine J Oudin, Tatsiana Kosciuk, et al.
The Journal of Investigative Dermatology
|
March 8, 2008
Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells
Konstantinos G Lasithiotakis, Tobias W Sinnberg, Birgit Schittek, et al.
Journal of the American Academy of Dermatology
|
July 21, 2015
Melanocytic nevi excised during B-Raf proto-oncogene (BRAF) inhibitor therapy: A study of 19 lesions from 10 patients
Mark C Mochel, Marc R Hammond, Dennie T Frederick, et al.
Page
of 42